miRNAs in the Beta Cell—Friends or Foes?
Endocrinology · 2023
DOI: 10.1210/endocr/bqad040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, 2023. Verfasst von Alexandros Karagiannopoulos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences in Malmö, Unit of Islet Cell Exocytosis, Lund University Diabetes Centre, Lund University, Skåne University Hospital,…. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, MicroRNAs, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Foundation for Strategic Research, Swedish Research Council.
Abstract (Originalsprache)
Type 2 diabetes (T2D) develops due to insulin resistance and an inability of the pancreatic β-cells to increase secretion of insulin and reduce elevated blood glucose levels. Diminished β-cell function and mass have been implicated in impaired β-cell secretory capacity and several microRNAs (miRNAs) have been reported to be involved in regulating β-cell processes. We believe miRNAs are nodes in important miRNA-mRNA networks regulating β-cell function and that miRNAs therefore can be targets for the treatment of T2D. MicroRNAs are short (≈19-23 nucleotides [nt]) endogenous noncoding RNAs which regulate gene expression by directly binding to the mRNA of their target genes. Under normal circumstances, miRNAs act as rheostats to keep expression of their gene targets at optimal levels for different β-cell outputs. In T2D, levels of some miRNAs are altered as part of the compensatory mechanism to improve insulin secretion. Other miRNAs are differentially expressed as part of the process of T2D pathogenesis, which results in reduced insulin secretion and increased blood glucose. In this review, we present recent findings concerning miRNAs in islets and in insulin-secreting cells, and their differential expression in diabetes, with a specific focus on miRNAs involved in β-cell apoptosis/proliferation and glucose-stimulated insulin secretion. We present thoughts around miRNA-mRNA networks and miRNAs as both therapeutic targets to improve insulin secretion and as circulating biomarkers of diabetes. Overall, we hope to convince you that miRNAs in β-cells are essential for regulating β-cell function and can in the future be of clinical use in the treatment and/or prevention of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences in Malmö, Unit of Islet Cell Exocytosis, Lund University Diabetes Centre, Lund University, Skåne University Hospital, 205 02 Malmö, Sweden.
ORCID-Profile: Lena Eliasson
Förderung
- Swedish Foundation for Strategic Research
- Swedish Research Council
Zitieren
APA
Karagiannopoulos, A., Cowan, E., & Eliasson, L. (2023). miRNAs in the Beta Cell—Friends or Foes?. Endocrinology. https://doi.org/10.1210/endocr/bqad040
Vancouver
Karagiannopoulos A, Cowan E, Eliasson L. miRNAs in the Beta Cell—Friends or Foes?. Endocrinology. 2023. doi:10.1210/endocr/bqad040
BibTeX
@article{Karagiannopoulos2023,
author = {Karagiannopoulos, Alexandros and Cowan, Elaine and Eliasson, Lena},
title = {miRNAs in the Beta Cell—Friends or Foes?},
journal = {Endocrinology},
year = {2023},
doi = {10.1210/endocr/bqad040}
}
EUVIMED